Christina Henderson

Christina is an experienced Project Manager with a strong multidisciplinary knowledge of different phases of new product development, including pre-clinical and toxicology testing, early clinical development, and regulatory submissions. Christina has been overseeing the development of the UQ Rapid Response Vaccine Pipeline since 2019, including through the 2020 CEPI funded emergency response to SARS-CoV-2. Christina is responsible for day-to-day project coordination, budget management, procurement, contract management, record keeping and reporting. She also oversees and coordinates a large consortium of Australia’s leading scientific organisations and several local and overseas professional vendors working on the project. Christina is hard-working, collaborative, and passionate about contributing to the development and commercialisation of life-saving medicine.

Qualification:

Bachelor of Biotechnology Innovation with Honours, QUT

Master of Business, University of Queensland

Publication:

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Chappell, Keith J., Mordant, Francesca L., Li, Zheyi, Wijesundara, Danushka K., Ellenberg, Paula, Lackenby, Julia A., Cheung, Stacey T. M., Modhiran, Naphak, Avumegah, Michael S., Henderson, Christina L., Hoger, Kym, Griffin, Paul, Bennet, Jillian, Hensen, Luca, Zhang, Wuji, Nguyen, Thi H. O., Marrero-Hernandez, Sara, Selva, Kevin J., Chung, Amy W., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Nicholson, Suellen, Corby, Stavroula, Holgate, Thomas, Wines, Bruce D., Hogarth, P Mark, Kedzierska, Katherine, ... Munro, Trent P. (2021). Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Infectious Diseases 21 (10) 1383-1394.

https://doi.org/10.1016/S1473-3099(21)00200-0